We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal judge threw out a case against GlaxoSmithKline that was part of multidistrict litigation over the labeling of its diabetes drug Avandia. Read More
The Federal Circuit upheld the Patent Trial and Appeal Board’s invalidation of Daiichi Sankyo’s patents for the anti-clotting drug Effient (prasugrel). Read More
Lawmakers once again waded into the reasons for rising drug prices, as a House panel invited a diverse group of industry representatives to weigh in on the main causes and to propose solutions. Read More
The Senate’s health committee held its final hearing in a set of three this year on the rising costs of prescription drugs — this time exploring how value-based pricing could help make payments more efficient, although it brings its own set of challenges. Read More
The FDA finalized its guidance on drug advertisements, clarifying the legal requirements for companies in the placement of the product’s name — as well as its size, prominence and frequency in promotional labeling, and the juxtaposition between branded and active ingredient names. Read More
U.S. healthcare spending growth slowed in 2016, including a steep drop in spending on retail prescription drugs — decelerating after two years of faster growth associated with coverage expansions under the Affordable Care Act, according to the Centers for Medicare and Medicaid Services. Read More
Janssen Biotech and Samsung Bioepis jointly requested that Janssen’s patent infringement case be dismissed following the Supreme Court’s ruling earlier this year on the biosimilar approval process. The New Jersey federal court agreed to the motion last week. Read More
Many manufacturers are offering larger rebates on medicines, but in many cases patients do not share in the negotiated discounts, according to a new analysis from PhRMA. Read More